Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Torii Gets Japan Rights to Verrica’s Wart Drug
Torii Pharmaceutical, a subsidiary of Japan Tobacco, said on March 17 that it has exercised its option to acquire exclusive rights to develop and commercialize Verrica Pharmaceuticals’ skin disease drug candidate VP-102 in Japan. Under their pact, Torii will hold…
To read the full story
Related Article
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Torii Gets Japan Option Rights to Verrica’s Warts Drug
August 6, 2020
BUSINESS
- Astellas Confirms Applying to US MFN Medicaid Pricing Model
July 7, 2026
- Otsuka’s Astex Inks Breast Cancer R&D Pact with Genentech
July 7, 2026
- Ribomic, Fujifilm to Join Forces on LNP CDMO Services
July 7, 2026
- Toray Unveils Next-Generation Opioid Painkiller Candidate
July 7, 2026
- Keytruda’s No. 1 Streak Reaches 33 Months: Encise
July 7, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…